From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars.

Krishnan A, Bp S, Mehta G, Ramaswamy S, Chakraborty S, Mandal S.

Open source

DOI
10.1080/17576180.2026.2715917
Published
2026-07-01
Container
Bioanalysis
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/17576180.2026.2715917,
  title = {From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars.},
  author = {Krishnan A and  Bp S and  Mehta G and  Ramaswamy S and  Chakraborty S and  Mandal S.},
  year = {2026},
  journal = {Bioanalysis},
  doi = {10.1080/17576180.2026.2715917},
  url = {https://doi.org/10.1080/17576180.2026.2715917}
}

RIS

TY  - JOUR
TI  - From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars.
AU  - Krishnan A
AU  -  Bp S
AU  -  Mehta G
AU  -  Ramaswamy S
AU  -  Chakraborty S
AU  -  Mandal S.
PY  - 2026
JO  - Bioanalysis
DO  - 10.1080/17576180.2026.2715917
UR  - https://doi.org/10.1080/17576180.2026.2715917
ER  - 

APA

A, K., S, B., G, M., S, R., S, C., & S., M. (2026). From anti-drug antibody incidence to clinical relevance: interpreting highly sensitive immunogenicity assays in biosimilars.. Bioanalysis. https://doi.org/10.1080/17576180.2026.2715917

Source records